Teva Rockets Into A Profit-Taking Zone On Austedo's Big Sales Beat

Core Insights - Teva Pharmaceutical reported adjusted earnings of 78 cents per share on $4.48 billion in third-quarter sales, surpassing analyst expectations of 68 cents per share and $4.38 billion in sales [1] - The company raised its sales guidance for the drug Austedo to $2.05 billion to $2.15 billion, while lowering the low end of its full-year sales outlook by $200 million to a range of $16.8 billion to $17 billion [2] - Teva's stock surged 12% in premarket trading, breaking out of a cup-with-handle base and returning to its buy zone [3] Financial Performance - Teva's third-quarter sales of $4.48 billion represent an increase from $4.33 billion in the same period last year [1] - The adjusted earnings guidance for the full year has been raised to a range of $2.55 to $2.65 per share, compared to analyst expectations of $2.61 per share [2] Stock Market Activity - Teva's stock price increased to $22.91 after the earnings report, indicating strong market performance [3] - The stock had previously dipped below its entry point but managed to return to the buy zone, which extends up to $20.98 [3]